Updated Investor Deck Highlights Stronger Efficacy Signal for GX-03 in Atopic Dermatitis
TTRX has more than doubled off its 52-week low of $2.57.
Summary
Turn Therapeutics' updated investor presentation shows a stronger efficacy signal for GX-03 in atopic dermatitis when enriched for itch severity, with a 53.2% treatment difference in the key endpoint and a clean safety profile.
Key Events · Product Development and Regulatory · TTRX
-
GX-03 Shows Stronger Efficacy in Enriched Population
In the PP-NRS≥7 subgroup (n=25), GX-03 achieved 61.5% Week 4 vIGA-AD success vs 8.3% for vehicle — a 53.2% treatment difference (p=0.0123), versus 28.8% in the full ITT population.
-
Clean Stage 1 Safety Profile
Stage 1 safety summary (N=50) showed zero serious adverse events, zero Grade ≥2 AEs, and zero discontinuations due to study drug across both GX-03 and vehicle arms.
-
Stage 2 Design Optimized for Registrational Endpoint
Stage 2 (N≈135) uses prospective stratification by baseline EASI with mandatory PP-NRS≥7 and vIGA-AD≥3, powered to ≥99.8% for the Week 4 vIGA-AD success endpoint.
-
Cash Runway Extended into Q3 2027
Company disclosed $10.3M cash balance as of June 30, 2026, with ~$1M/quarter G&A burn and additional capital available under existing facilities.
Analysis · TTRX · Life Sciences
The October 6 investor presentation reveals materially stronger Phase 2 data for GX-03 in atopic dermatitis than previously disclosed. Enriching for patients with baseline itch severity (PP-NRS≥7) produced a 53.2% treatment difference in the Week 4 vIGA-AD success endpoint (61.5% vs 8.3%, p=0.0123), versus a 28.8% difference in the full ITT population. The company also disclosed a clean Stage 1 safety profile with zero serious adverse events, and confirmed a cash runway into Q3 2027 with $10.3M on hand. These data strengthen the case for the registrational endpoint selection and de-risk the upcoming FDA Type B meeting in Q4 2026.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TTRX was trading at $11.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $346.7M. The 52-week trading range was $2.57 to $26.50. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.